Choose Your Country or Region

Osimertinib (AZD9291)

Name: Osimertinib (AZD9291)
Brand: Selleck Chemicals
SKU: S7297
Rating: 5 (301 reviews)

Catalog No.S7297 Synonyms: Mereletinib

For research use only.

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

Osimertinib (AZD9291) Chemical Structure

CAS No. 1421373-65-0

Selleck's Osimertinib (AZD9291) has been cited by 301 publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Related Compound Libraries

Other EGFR Products

Erlotinib (OSI-774)^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B)^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.
Erlotinib (OSI-774) HCl

Erlotinib (OSI-774, CP358774, NSC 718781) HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Download Inhibitor Catalog

EGFR Signaling Pathway Map

Biological Activity

Description

Features

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

Targets

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

In vitro

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

PC-9/BRc1	Mof1SpVv[3Srb36gRZN{[Xl?	MWi1NEBvVQ>?	NIr2RWgzPCCq	MWPEUXNQ	MnjPbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	M1zxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC-9/ERc1	M1jQbGZ2dmO2aX;uJGF{e2G7	NHK0SlY2OCCwTR?=	M1S0eVI1KGh?	M1T5S2ROW09?	MYDpcoR2[2W\|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?=	NXr5bY5sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2	MWLGeY5kfGmxbjDBd5NigQ>?	NV;iT\|A3PTBibl2=	MYiyOEBp	M1LHe2ROW09?	NIf4Z2JqdmS3Y3XzJIV5eHKnc4Ppc44hd2ZidHjlJJBzd2Gyb4D0c5Rq[yCEQ1ytNkBn[W2rbImgcYVu[mW{IFLJUS=>	NYOyUG1QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv0S3E2OCCwTR?=	MmO0NVAh\A>?	MXrEUXNQ	NH3zb4VqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	M3PvcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC-9/ERc1	NFLNU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnG3OVAhdk1?	M4OybVExKGR?	NGLGRXVFVVOR	MVXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN?	NIPoTms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
VP-2	NXy1NIlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLPOVAhdk1?	NIDOTWcyOCCm	MknmSG1UVw>?	M3P1SYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC9 GR4	NV7xNoRQTnWwY4Tpc44hSXO\|YYm=	M4XYclAuOTBizszN	MmfUO\|IhcA>?		NVqzNJJIcW6qaXLpeJPDqEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\8Li	NWfIXFlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN\|PD;hQi=>
PC9	NHLDbIxHfW6ldHnvckBCe3OjeR?=	NWHqZpVpOC1zMDFOwG0>	MnvrO\|IhcA>?		MlOxbY5pcWKrdIOgW3QhTUeIUjDheEBtd3diY3;uZ4VvfHKjdHnvcpM>	M4fZe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 GR4	M4O3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;ZO4xUOC1zMDFOwG0>	NVqxTW9sPzJiaB?=		MVzpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NV3ONmNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN\|PD;hQi=>
BAF3	MVrGeY5kfGmxbjDhd5NigQ>?		NEPv[pA4OiCq		Mm\6S2k2OCB;IECuNFAxOyEQvF2=	NUPTPGNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	MUXGeY5kfGmxbjDhd5NigQ>?		M3LwZlczKGh?		Mk\WS2k2OCB;IECuNFAxOyEQvF2=	NIHlclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	MWPGeY5kfGmxbjDhd5NigQ>?		NYLPeYhVPzJiaB?=		M1S0bmdKPTBiPTCwMlAxOSEQvF2=	MoPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	NEfITFRHfW6ldHnvckBie3OjeR?=		Mn\nO\|IhcA>?		MVXHTVUxKD1iMD6wNFEh\|ryP	MmTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	MlnQSpVv[3Srb36gZZN{[Xl?		MlXKO\|IhcA>?		MoHnS2k2OCB;IECuNFAzKM7:TR?=	NEmxZlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	MXjGeY5kfGmxbjDhd5NigQ>?		NV7IcWlRPCCq		NXG4XWxRTUN3MDC9JFAvODB{IN88US=>	NFq1XZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	MXjGeY5kfGmxbjDhd5NigQ>?		Ml3rN{Bp		NWf6cGZwUUN3MDC9JFAvODB{NTFOwG0>	M4LFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
H1975	NYLFOmZqTnWwY4Tpc44h[XO\|YYm=		M1m1XFMhcA>?		Moi1TWM2OCB;IECuNFAzPSEQvF2=	NHL2OIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
H3255	MYXGeY5kfGmxbjDhd5NigQ>?		M1f2fFMhcA>?		MVzJR\|UxKD1iMD6wNFQyKM7:TR?=	NY[0WIp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N\|M5OjlpPkK3OFM{QDJ7PD;hQi=>
NCI-H1975	MlfGSpVv[3Srb36gZZN{[Xl?		NH\lTpg4OiCq		NULwTZcyT0l3MDC9JFAvODB3IN88US=>	Mo\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	NXXZNGVPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUK1TJJEPzJiaB?=		NIniVWpKSzVyIE2gNE4xODZ3IN88US=>	M{TBTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
NCI-H1975	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MXS3NkBp		NIrkZYJKSzVyIE2gNE4xOTB3IN88US=>	NFnLdnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
Sf21	MXnGeY5kfGmxbjDhd5NigQ>?				M1nrNGlEPTBiPTCwMlAyOiEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NkK2O{c,Ojd7OU[yOlc9N2F-
PC9-DRH	MXvGeY5kfGmxbjDhd5NigQ>?		MVKyJIg>		NYP6XVhEUUN3MDC9JFAvODF\|IN88US=>	NGLvS2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3	NFT0c2FHfW6ldHnvckBie3OjeR?=		M{HZVlczKGh?		NIHNbGFIUTVyIE2gNE4xOTNizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	NUOxfmRSTnWwY4Tpc44h[XO\|YYm=		M1nOTVk3KGh?		Mn7lSWM2OCB;IECuNFE1KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
HCC827	NF\vTGhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXK0NGJIQTZiaB?=		M4C1NWVEPTBiPTCwMlAyPCEQvF2=	MonYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
NCI-H1975	NUHp[oI2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MmLXPVYhcA>?		M{fIWWVEPTBiPTCwMlAyPCEQvF2=	NHLK[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	M2C5dGZ2dmO2aX;uJIF{e2G7		MkLpNkBp		MVHJR\|UxKD1iMD6wNVUh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
H1975	MUPGeY5kfGmxbjDhd5NigQ>?		MViyJIg>		Mn:4TWM2OCB;IECuNFE2KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
PC9	MXvGeY5kfGmxbjDhd5NigQ>?		MkXJNkBp		NGDmSHJKSzVyIE2gNE4xOTdizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
NCI-H1975	NEHUUpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NUnHS5hUPzJiaB?=		Mo\RTWM2OCB;IECuNFE6KM7:TR?=	M4PtblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
NCI-H1975	NFGw[XdHfW6ldHnvckBie3OjeR?=		MVe5OkBp		MnG4SWM2OCB;IECuNFE6KM7:TR?=	M4jYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
NCI-H1975	NW\KU3k{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NH\zPZI6PiCq		Ml;WSWM2OCB;IECuNFE6KM7:TR?=	M{C5V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkCzPVkyLz5{OE[wN\|k6OTxxYU6=
NCI-H1975	M2exXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NIX4eJA4OiCq		MYTJR\|UxKD1iMD6wNVkh\|ryP	M1zVWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|QxLz5{OUi1N\|M1ODxxYU6=
HCC827	MWPGeY5kfGmxbjDhd5NigQ>?		M1PsdVIhcA>?		MnqxTWM2OCB;IECuNFI{KM7:TR?=	NXH2bYJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	M2nMS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M1;4elczKGh?		NFzKelFKSzVyIE2gNE4xOjNizszN	NYPkWWxxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
PC9	MknZR5l1d3SxeHnjbZR6KGG\|c3H5		M3P3V\|czKGh?		NEDKfHRIUTVyIE2gNE4xOjNizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	MlnKR5l1d3SxeHnjbZR6KGG\|c3H5		MX[3NkBp		MlvRS2k2OCB;IECuNFI1KM7:TR?=	NY[4N3RXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
HCC827	NVO5cnRUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NVf6XIVnPzJiaB?=		MnfXTWM2OCB;IECuNFI2PCEQvF2=	MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
HCC827	NXrWZng2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MWO3NkBp		NXH1fWlpUUN3MDC9JFAvODJ5IN88US=>	MmPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MXm3NkBp		MXfJR\|UxKD1iMD6wNlch\|ryP	NFi1OG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975	M2jpbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{m5VlczKGh?		NVXIV21HUUN3MDC9JFAvODNizszN	NX3lcXloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|M2PzlpPkK4NFM{PTd7PD;hQi=>
H3255	MU\GeY5kfGmxbjDhd5NigQ>?		M3LRbFczKGh?		M13oeWdKPTBiPTCwMlA{OyEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	M{HrOmZ2dmO2aX;uJIF{e2G7		MX[yJIg>		NFrQO\|NKSzVyIE2gNE4xOzZizszN	NEm2[Y09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	NVPvVnczSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3PVV\|czKGh?		MVXJR\|UxKD1iMD6wOFEh\|ryP	NYHS[2h7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
NCI-H1975	M{fZOmZ2dmO2aX;uJIF{e2G7		NFTlflYyKGh?		M1;hUGlEPTBiPTCwMlA1OSEQvF2=	NX61PXZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
BAF3	NHP6S5NHfW6ldHnvckBie3OjeR?=		NH\5bpg1KGh?		M4PyWWVEPTBiPTCwMlA1OyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M{fzflczKGh?		NWrW[YQ2UUN3MDC9JFAvODR5MjFOwG0>	M1W4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
NCI-H1975	NHnLeYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXTnfXNRPzJiaB?=		MYPJR\|UxKD1iMD6wOVIh\|ryP	MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N\|koRjJ5MUOxOlM6RC:jPh?=
PC9	NVLrSYVLTnWwY4Tpc44h[XO\|YYm=		M3rGblIhcA>?		MoTpTWM2OCB;IECuNFU3KM7:TR?=	Mk[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
NCI-H1975	NYPCfolRS3m2b4TvfIlkcXS7IHHzd4F6		MnnKO\|IhcA>?		NIL3fnRKSzVyIE2gNE4xPiEQvF2=	NXm4eVBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
HCC827	M{Hte2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				NHKye\|hKSzVyIE2gNE4xPjF4IN88US=>	MnO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
NCI-H1975	NFLIUmVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				M3L4bWlEPTBiPTCwMlA3PyEQvF2=	M334NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HaCaT	M4HZPGZ2dmO2aX;uJIF{e2G7		NIni[ZY{KGh?		NXrBWmxiUUN3MDC9JFAvODd\|NzFOwG0>	M3LhOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
NCI-H1975	NHK0NVFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NY\sPIhFPzJiaB?=		MV3JR\|UxKD1iMD6xN{DPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431	NITSOIxHfW6ldHnvckBie3OjeR?=		NIXvPGwyKGh?		NXfORlhuUUN3MDC9JFAvOTRzIN88US=>	M{nnTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVI3Lz5{OUWzOFkzPjxxYU6=
A549	M2\UTmZ2dmO2aX;uJIF{e2G7				NFjOO2VKSzVyIE2gNE4yPSEQvF2=	NHnsZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
Calu3	NV\2dW5US3m2b4TvfIlkcXS7IHHzd4F6		MX23NkBp		NXfie\|N7T0l3MDC9JFAvOjZ2IN88US=>	NWDmTItyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
Sf9	MVjGeY5kfGmxbjDhd5NigQ>?		M1PXXVIxKG2rboO=		MnSxTWM2OCB;IECuNlc5KM7:TR?=	NV;pfopXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFIyPTFpPkK4OFgzOTVzPD;hQi=>
BAF3	M2j1d2Z2dmO2aX;uJIF{e2G7		MW[3NkBp		NUPJOldZT0l3MDC9JFAvOyEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	M1zqNWZ2dmO2aX;uJIF{e2G7		NYH0Vo9SPzJiaB?=		NF70fWxIUTVyIE2gNE4{OSEQvF2=	NIjCWJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H460	M2LQNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NITJfGs4OiCq		M{TaT2lEPTBiPTCwMlQyPTlizszN	MkfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
LoVo	MUHGeY5kfGmxbjDhd5NigQ>?		Moi0NkBp		MlvjTWM2OCB;IECuOFgh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo	NVfTe4tVTnWwY4Tpc44h[XO\|YYm=		MmDJNkBp		MWrJR\|UxKD1iMD60PEDPxE1?	NGX5fZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
A549	MlznRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnjSO\|IhcA>?		MYPJR\|UxKD1iMD60PFYh\|ryP	NYDnbWJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
BAF3	M2PPS2Z2dmO2aX;uJIF{e2G7		MXG3NkBp		NIHCWYNIUTVyIE2gNE42KM7:TR?=	MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A549	M{PiRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NYXIS5M{PzJiaB?=		NWPyO2pPUUN3MDC9JFAvPTNizszN	NV3yWG5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
A549	MkO4R5l1d3SxeHnjbZR6KGG\|c3H5		MX23NkBp		Mn:yTWM2OCB;IECuOVMh\|ryP	NGezZ4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
BAF3	NY\CUZBTTnWwY4Tpc44h[XO\|YYm=		MWq3NkBp		M{PTUmdKPTBiPTCwMlU2KM7:TR?=	NGrjTZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NHKySXhHfW6ldHnvckBie3OjeR?=		MkLwO\|IhcA>?		M2naO2dKPTBiPTCwMlU3KM7:TR?=	M2\6e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HEK293	MWTGeY5kfGmxbjDhd5NigQ>?				NVXZR4RYUUN3MDC9JFAvPTdizszN	M{mwd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3	NXizUlh2TnWwY4Tpc44h[XO\|YYm=		MVG3NkBp		MWXHTVUxKD1iMD61PUDPxE1?	M1mwc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431	M2PZVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				M1jQRWlEPTBiPTCwMlYyPTZizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
HT-29	M3z6SmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHHUe2E4OiCq		MX3JR\|UxKD1iMD62OUDPxE1?	NXfEN49HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
A431	Ml;MSpVv[3Srb36gZZN{[Xl?		NXjTc3J2QTZiaB?=		NUHHNlhYTUN3MDC9JFAvPjZ5IN88US=>	M2DlTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
A431	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NIr1WVQ6PiCq		MofXSWM2OCB;IECuOlch\|ryP	NYTUd2h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
A431	NVrNSphsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MV[3NkBp		NHL4UFlKSzVyIE2gNE43QDVizszN	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
A431	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NWLhSVl7QTZiaB?=		NV3GNpJvTUN3MDC9JFAvPyEQvF2=	NET3VnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN\|k6OSd-Mki2NFM6QTF:L3G+
A549	MorXR5l1d3SxeHnjbZR6KGG\|c3H5		NXn1XXlTPzJiaB?=		NISxfHVKSzVyIE2gNE45PyEQvF2=	Ml;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
A431	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NHf2W2M4OiCq		MUXJR\|UxKD1iMD64PVMh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
BA/F3	NVX2TVBDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MVm3NkBp		NYPXNpV[UUN3MDC9JFEh\|ryP	NVXJT\|F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
BAF3	MnfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2\mO\|czKGh?		NYLW[41nT0l3MDC9JFEvOiEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H2122	NGrQc25HfW6ldHnvckBie3OjeR?=		MUm3NkBp		NHH1R5RIUTVyIE2gNU4zKM7:TR?=	Mnj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A431	M3rMTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NEm5NZY4OiCq		MlGyTWM2OCB;IEGuNlQh\|ryP	NWmwUFZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
A431	MojTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NVTkR4J{PzJiaB?=		M1PwcGlEPTBiPTCxMlI3KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
A431	M1\wemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NX2zUo81PzJiaB?=		MV\JR\|UxKD1iMT62NFQh\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|M{W3PUc,OjhyM{O1O\|k9N2F-
A549	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MVW5OkBp		NIjhWohGSzVyIE2gNU45OyEQvF2=	MlPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
CHL	MmfzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHzYPJg4OiCq		NIDXN4dIUTVyIE2gNk46KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1355	MUHGeY5kfGmxbjDhd5NigQ>?		M4C1dVczKGh?		MULHTVUxKD1iMzFOwG0>	NYjCfG5SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H1703	NH[4PZJHfW6ldHnvckBie3OjeR?=		NXLPSHR7PzJiaB?=		MoTpS2k2OCB;IEOuOUDPxE1?	NGrjRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A549	M3WxR2Z2dmO2aX;uJIF{e2G7		NIXGbFA4OiCq		NG\SZpJIUTVyIE2gN{42KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
CHO	NVvIXlg{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVPLSnpCPzJiaB?=		MnPkS2k2OCB;IESuNkDPxE1?	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3	NWLSTmx6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NVjhToxbPzJiaB?=		M2LMd2lEPTBiPTC0MlYyKM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BAF3	NUi0NWZbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NV\1TXk5PzJiaB?=		MV3JR\|UxKD1iNT6xOUDPxE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BEAS2B	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MWm3NkBp		MnjGTWM2OCB;IEG0Mlkh\|ryP	NWTOSXpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
NCI-H1975	MlLqSpVv[3Srb36gZZN{[Xl?		NF\EW40zKGh?		NX22eWdtUUN3MDC9JFE2KM7:TR?=	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
PC9	M3z1TWZ2dmO2aX;uJIF{e2G7		M2K0TlIhcA>?		NIrMPJBKSzVyIE2gNVch\|ryP	M4fjUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
LoVo	MkDlSpVv[3Srb36gZZN{[Xl?		Mk\LNkBp		NIHEOJRKSzVyIE2gOFgxKM7:TR?=	M{DXUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	MXXBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				NX3F[3k3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q6PzCPIHTveYJt\SCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB{LkWgcYcwc2dxZHH5MEBxdyCzZDDmc5IhPyCmYYnzJJJmdGG2aY\lJJRwKGOxboTyc4w>	NGHs[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
rat hepatocytes	MV;GeY5kfGmxbjDhd5NigQ>?				MkfsTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK\|Yh[2WubIO=	MkLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
human hepatocytes	MmC3SpVv[3Srb36gZZN{[Xl?				NIrr[49KdnS{aX7zbYMh[2ynYYLhcoNmKGmwIHj1cYFvKGincHH0c4N6fGW\|IH3lZZN2emWmIIDldkAyOCd4IHPlcIx{	M17ZblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	MU\BcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				NGrxb2xCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDVibXevb4cw\GG7LDDwc{By\CCob4KgO{Bl[Xm\|IILlcIF1cX[nIITvJINwdnS{b3y=	NH:4[3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	Mn3MSpVv[3Srb36gZZN{[Xl?				NUm0d4ZJW2WuZXP0bZZqfHliaX7k[ZgtKHKjdHnvJI9nKEmFNUCg[o9zKEWJRmKgWFc6OE1xTEi1PHIh\G:3YnzlJI12fGGwdDDlfJBz\XO\|aX7nJIh2dWGwIF7DTU1JOTl5NTDj[YxteyC2bzDJR\|UxKG[xcjD3bYxlKHS7cHWgSWdHWiCneIDy[ZN{cW6pIHj1cYFvKEF2M{GgZ4VtdHN?	NHXOcIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
NCI-H1975	Mne2RY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NVTEdYVrSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhTUeIUjDUO\|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJGJCVEJxYzDheIh6dWmlIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOTBibXevb4ctKHCxIHLp[EBnd3JiMkGg[IF6ew>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
HCC827	NX75N5g5SXCxcITvd4l{KGG\|c3H5				M4PiWmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOg[YFzdHliYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEGuN\|QmMQ>?	MmjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	NG\1eZBCeG:ydH;zbZMh[XO\|YYm=				M4ToZ2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOgcIF1\SCjcH;weI91cWNiY3XscJMh[XRiMzD1UUBi\nSncjCyOEBpenNiYomgRY5v\XirbjDWMWZKXENxcILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eTCoVpZjKD1iMkeuNVQmMQ>?	NFn1bGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549	M3PIWGZ2dmO2aX;uJIF{e2G7				M37KVnNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJGE2PDliY3XscJMh\XiycnXzd4lv\yC5aXzkMZR6eGViRVfGVk9MNVKjczDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCmb4XicIUhdXW2YX70	MkjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827	NH:xNoRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MlnVO\|IhcA>?		MmHwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZZQhOSC3TTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	M2nWUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3	NULoUWVOTnWwY4Tpc44h[XO\|YYm=		NFnFPYszKGh?		MmXKTY5pcWKrdHnvckBw\iCHR1\SJHQ4QTCPL1y4OVhTN0N5OUfTJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFS2YucW6mdXPl[EBz\WOncITvdkBxcG:\|cHjvdplt[XSrb36gZZQhOSC2bzCzJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NHXXb5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
BAF3	NHP2fFdHfW6ldHnvckBie3OjeR?=		M2TGPVIhcA>?		NUHpWZJIUW6qaXLpeIlwdiCxZjDFS2ZTKDF7RD;UO\|kxVS:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
NCI-H1975	Mn3VRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				MkS5RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJHNVV0ONLV\vfI4ydnVxTnr1JI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYYSgNlAhdWdxa3ev[IF6NCCybzDx[EBnd3JiMUSg[IF6eyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?=	NIflfGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIyQSd-MkizPVUzOTl:L3G+
Caco2	MoPYSpVv[3Srb36gZZN{[Xl?		NUjPWnI5OiCq		MXTF[oZtfXhicnH0bY8hd2ZiYYDwZZJmdnRicHXycYVi[mmuaYT5JIZzd21iYnHzc4xifGW{YXygd4ll\SC2bzDhdIlk[Wxic3nk[UBwfmW{IHHwbYNidCC\|aXTlJJRwKGKjc3;sZZRmemGuIIPp[IUhd3[ncjDpckBpfW2jbjDDZYNwOiClZXzsd{BifCB3IIXNJIlv[3WkYYTl[EBnd3JiMjDodpM>	NHz5O4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
A431	M{Xi[2Z2dmO2aX;uJIF{e2G7				M17INXNmdGWldHn2bZR6KHKjdHnvJI9nKEWFNUCg[o9zKGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVkB1dyCHQ{WwJIZweiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJvTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfA>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	NVztSYdWTnWwY4Tpc44h[XO\|YYm=		Mon3NkBp		M361NWFxeGG{ZX70JJBmem2nYXLpcIl1gSCjY4Lvd5Mh[XCrY3HsJJRwKGKjc3;sZZRmemGuIIPp[IUhcW5iaIXtZY4hS2Glb{KgZ4VtdHNiYYSgOUB2VSCrbnP1ZoF1\WRiZn;yJFIhcHK\|	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	MoK3SpVv[3Srb36gZZN{[Xl?		MVyyJIg>		NIO3NWhCeHCjcnXueEBx\XKvZXHibYxqfHliYXPyc5N{KGKjc3;sZZRmemGuIITvJIFxcWOjbDDzbYRmKGmwIHj1cYFvKEOjY3:yJINmdGy\|IHH0JFUhfU1iaX7jeYJifGWmIH\vdkAzKGi{cx?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
NCI-H1975	MVrGeY5kfGmxbjDhd5NigQ>?		NU\CUG1iPCCq		NV7TclVSUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfCCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFsfCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN\|A5N1OnckS3N{B{cXSnIHH0JFEhfU1ibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NXzRcWxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	NGq0SmVHfW6ldHnvckBie3OjeR?=		MUK0JIg>		M4D0VWlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJI12fGGwdDDpckBpfW2jbjDIR2M5OjdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFsfCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN\|A5N1OnckS3N{B{cXSnIHH0JFEhfU1ibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MkjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	M4S4fGFxd3C2b4Ppd{Bie3OjeR?=		M3myWFQ5KGh?		MUXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBufXSjboSgZZN{\XO\|ZXSgZZMh[2G\|cHHz[VMh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	M{\FU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	MV3BdI9xfG:\|aYOgZZN{[Xl?		MkjqOFghcA>?		MnjrTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\S1\|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NVrqeWs6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	NG\YdnhCeG:ydH;zbZMh[XO\|YYm=		Mn;vOFghcA>?		MX;JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFCFOTDj[YxteyCqYYLic5JqdmdiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bk[XOyYYPlMVMh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	M{\USlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	NHy1VGtCeG:ydH;zbZMh[XO\|YYm=		NUfiOI44PDhiaB?=		M1nLTWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSEOyOVUh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIhdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	MnPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	MXXBdI9xfG:\|aYOgZZN{[Xl?		MUG0PEBp		Mn;CTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc>	NH\ncpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9	NIG0fYVCeG:ydH;zbZMh[XO\|YYm=		MX60PEBp		MXLJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFCFOTDj[YxteyCqYYLic5JqdmdiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NIrFdlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	MofFRZBweHSxc3nzJIF{e2G7		MVq0PEBp		MYrJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	NVrRUZlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	Ml30RZBweHSxc3nzJIF{e2G7		M{TNblQ5KGh?		NHHDZ25KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	M16zW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	M1\kZ2Z2dmO2aX;uJIF{e2G7				MorBV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQhfG9iSVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCqYYLic5Jqdmdid3ns[E11gXCnIFXHSnI>	Mme2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
human hepatocytes	NGjOZXNHfW6ldHnvckBie3OjeR?=				MnLLTY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgcYltdGmxbjDj[Yxtew>?	MlrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
rat hepatocytes	NFG3RVVHfW6ldHnvckBie3OjeR?=				MYfJcpRzcW6\|aXOgZ4xm[XKjbnPlJIlvKHKjdDDo[ZBifG:leYTld{Bie3Onc4Pl[EBx\XJibXnscIlwdiClZXzsdy=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
A549, NCI-H1975	NXviW\|hLTnWwY4Tpc44h[XO\|YYm=				M13iXnNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHnuJIh2dWGwIF7DTU1JOTl5NTDj[Yxtew>?	M4L2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
A549, PC9	M4DlVGZ2dmO2aX;uJIF{e2G7				M4jFb3NmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iUFO5JINmdGy\|	M3v3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827	MX7BdI9xfG:\|aYOgZZN{[Xl?				NYrtUoZkUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO\|UxKGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCnYYLsfUBieG:ydH;0bYMh[2WubIOgZZQhOyC3TTDh[pRmeiB{NDDodpMh[nliQX7u[ZhqdiCYLV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgSBqUo\iJF0hOS5\|NDD0c{AyNjZ5JTm=	M1rhflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|QxLz5{OUi1N\|M1ODxxYU6=
NCI-H1975	MnrySpVv[3Srb36gZZN{[Xl?				MmC3TY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJGVITi2\|dHnteYxifGWmIHj1cYFvKE6FST3INVk4PSClZXzsd{BifCBzIITvJFExOCCwTTDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	NXj2PJdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5NFYyOTRpPkK5PVA3OTF2PD;hQi=>
A431	MX;GeY5kfGmxbjDhd5NigQ>?				MlPvV4Vt\WO2aY\peJkhemG2aX:sJJJifGmxIFnDOVAh\m:{IHj1cYFvKEF2M{GgZ4VtdHNib4\ldoV5eHKnc4Ppcochf2muZD30fZBmKEWJRmKgeI8hUUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHX4dJJme3OrbnegSWdHWiCWN{mwUU9NQDV6UjDteZRidnR?	NEfaR2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN\|E3Ozl:L3G+
PC9	Mln2RY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NEfzUWVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|kh[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCjY4TpeoF1cW6pIH31eIFvfCC6ZX7v[5Ji\nSnZDDpckBUS0mGIH3veZNmKGG\|c3Xzd4VlKGG\|IIT1cY9zKGe{b4f0bEBqdmirYnn0bY9vKGG2IEGwJI1oN2upL3ThfUwheG9icXSg[o9zKDdiZHH5d{Bz\WyjdHn2[UB1dyClb370do9t	MmLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
A431	MoTkRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				M2[5c2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N\|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u	NVKxW49XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-EGFR / p-AKT / p-ERK ; ABCB1	28416483 27649127
Growth inhibition assay	Cell viability	31043587
Immunofluorescence	Ki67 / γH2AX / p16	29212784

In vivo

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]

Protocol (from reference)

Animal Research: ^[2]	Animal Models: Mice bearing PC9 and H1975 xenograft tumors Dosages: ~5 mg/kg Administration: p.o.

References

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	7.5mg/mL

Chemical Information

Molecular Weight	499.61
Formula	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

Download Osimertinib (AZD9291) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04591002	Suspended	Drug: Osimertinib 80 MG	Lung Cancer	Samsung Medical Center	November 18 2022	Phase 2
NCT05401110	Not yet recruiting	Drug: Osimertinib\|Drug: Carotuximab	Non Small Cell Lung Cancer\|Lung Cancer	Karen Reckamp MD MS\|Enviro Therapeutics Inc.\|Cedars-Sinai Medical Center	August 2022	Phase 1
NCT05166616	Recruiting	Procedure: Biopsy\|Drug: Osimertinib\|Drug: Triptolide Analog	Advanced Lung Non-Small Cell Carcinoma\|Locally Advanced Lung Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8\|Unresectable Lung Non-Small Cell Carcinoma	City of Hope Medical Center\|National Cancer Institute (NCI)	July 1 2022	Phase 1
NCT05120349	Recruiting	Drug: Osimertinib\|Drug: Placebo	Non-Small Cell Lung Cancer	AstraZeneca	February 21 2022	Phase 3
NCT05298176	Recruiting	Drug: Afatinib Osimertinib Carboplatin and Pemetrexed	Non-Small Cell Lung Cancer	Amsterdam UMC location VUmc	January 4 2022	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

Answer:
Osimertinib can be used for animal study. The vehicle we suggest is: 5%DMSO+40%PEG300+5%Tween 80+50%ddH2O.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):